natgillin/translations-raw huggingface dataset:
In combined female fertility, early embryonic and embryofoetal development studies in rats numbers of ovarian corpora lutea were reduced in pregnant females at 300 mg/kg/day (approximately 3 times human clinical exposure based on AUC), but there were no effects on oestrous cycle, mating or fertility indices.
V kombiniranih študijah plodnosti samic, zgodnjega embrionalnega ter embriofetalnega razvoja pri podganah se je število rumenih telesc v jajčniku pri brejih podganah ob odmerku 300 mg/kg/dan (to je približno 3-kratna klinična izpostavljenost pri človeku na podlagi AUC) zmanjšalo, ni pa bilo vplivov na estrusni ciklus, parjenje ali indekse plodnosti.
In combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability.
Pri sočasni upoarbi topotekana z drugimi kemoterapevtiki bo morda zaradi boljšega prenašanja potrebno zmanjšati odmerek vsakega zdravila.
In combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability.
Pri sočasni uporabi topotekana z drugimi zdravili za kemoterapijo je lahko potrebno zmanjšanje odmerka vsakega od zdravil zaradi boljšega prenašanja terapije.
In COMFORT-I (MF patients) the mean increase from baseline in systolic BP was 0-2 mmHg on Jakavi versus a decrease of 2-5 mmHg in the placebo arm.
V študiji COMFORT-I (z bolniki z mielofibrozo) je pri bolnikih, ki so prejemali zdravilo Jakavi, znašalo zvišanje sistoličnega krvnega tlaka od izhodiščne vrednosti v povprečju 0-2 mmHg v primerjavi z znižanjem za 2-5 mmHg v skupini bolnikov, ki so prejemali placebo.
In COMFORT-I, 45.9% subjects in the Jakavi group achieved a ≥50% improvement from baseline in the week 24 total symptom score (measured using MFSAF diary v2.0), as compared to 5.3% in the placebo group (p<0.0001 using chi-square test).
V študiji COMFORT-I je pri 45,9 % preiskovancev v skupini z zdravilom Jakavi prišlo do najmanj 50-odstotnega izboljšanja skupne ocene vseh simptomov od izhodišča do konca 24. tedna (kar so ocenjevali s pomočjo dnevnika z obrazcem MFSAF različica 2.0) v primerjavi s 5,3 % bolnikov s takim izboljšanjem v skupini s placebom (p<0,0001 pri uporabi testa hi-kvadrat).
In COMFORT-II mean values showed little difference between the ruxolitinib-treated and the control-treated MF patients.
V študiji COMFORT-II so se povprečne vrednosti pri bolnikih, ki so prejemali ruksolitinib, le malo razlikovale od tistih pri kontrolnih bolnikih z mielofibrozo.
In common with other monoclonal antibodies, reslizumab is believed to be degraded by enzymatic proteolysis into small peptides and amino acids.
Kot za druga monoklonska protitelesa prevladuje mnenje tudi za reslizumab, da se z encimsko proteolizo razgrajuje v majhne peptide in aminokisline.
In comparative trials with different doses of Ovitrelle, the following adverse reactions were found to be associated with Ovitrelle in a doserelated fashion: OHSS, vomiting and nausea.
V primerjalnih študijah z različnimi odmerki zdravila Ovitrelle, so ugotovili, da so naslednje neželene reakcije povezane z velikostjo odmerka zdravila Ovitrelle: OHSS, bruhanje in slabost.
In comparator oral studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia.
V primerjalnih študijah peroralnega olanzapina, ki so trajale eno leto ali manj, so olanzapin povezovali s statistično značilno manjšo incidenco diskinezij, ki se pojavijo ob zdravljenju.
In comparison to bioptic diagnostics of an infection with Helicobacter pylori, the breath test achieved in a clinical trial on 168 patients from the age of 3 to 11, a sensitivity of 98.4 % [90 %-CI:
V primerjavi z bioptično diagnostiko okužbe s Helicobacter pylori je dihalni test v kliničnih preskušanjih na 168 bolnikih v starosti 3 – 11 let je dosegel občutljivost 98,4 % [90 %-IZ: ≥91,3 %] in specifičnost 98,1 % [90 %-IZ:
In comparison to bioptic diagnostics of an infection with Helicobacter pylori, the breath test achieved in clinical trials on 457 patients, a sensitivity in the range of 96.5 % to 97.9 % [95 %-CI: 94.05 %-99.72 %], and a specificity range from 96.7 % to 100 % [95 %-CI: 94.17 %-103.63 %].
V primerjavi z bioptično diagnostiko okužbe s Helicobacter pylori je dihalni test v kliničnih preskušanjih na 457 bolnikih dosegel obseg občutljivosti 96,5 % do 97,9 % [95 %-interval zaupanja, IZ: 94,05 % - 99,72 %] in obseg specifičnosti od 96,7 % do 100 % [95 %-IZ: 94,17 % - 103,63 %].
In comparison to bioptic diagnostics of an infection with Helicobacter pylori, the breath test achieved in clinical trials on 457 patients, a sensitivity in the range of 96.5 % to 97.9 % [95 %-CI: 94.05 %-99.72 %], and a specificity range from 96.7 % to 100 %. [95 %-CI: 94.17 %-103.63 %].
V primerjavi z bioptično diagnostiko okužbe s Helicobacter pylori je dihalni test v kliničnih preskušanjih na 457 bolnikih dosegel obseg občutljivosti 96,5 % do 97,9 % [95 %-interval zaupanja, IZ: 94,05 % - 99,72 %] in obseg specifičnosti od 96,7 % do 100 % [95 %-IZ: 94,17 % - 103,63 %].
In comparison to Caucasians, black patients may require higher tacrolimus doses to achieve similar trough levels.
Pri bolnikih črne rase bodo za dosego enakih najnižjih koncentracij morda potrebni višji odmerki takrolimusa kot pri belcih.
In comparison with biopsy based techniques for diagnosing H. pylori infection, using data from two therapeutic trials, Pylobactell achieved during different conditions (pre-study and follow-up visits) sensitivity estimates above 95% with lower one-sided 95% confidence limit ranging from 93% to 98%.
V primerjavi z metodami za ugotavljanje infekcije s H. pylori, ki temeljijo na biopsiji, ob upoštevanju podatkov dveh terapevtskih preskušanj, je Pylobactell pod različnimi pogoji (pred študijo in ob kontrolnih pregledih bolnikov po zdravljenju) dosegel ocene občutljivosti nad 95 % s spodnjo enostransko 95 % mejo zaupanja z ustreznimi spodnjimi mejami zaupanja od 93 % do 98 %.
In comparison, none of the 44 patients receiving placebo had stable haemoglobin levels, and they needed an average of 10 transfusions.
V primerjavi s tem ni imel noben od 44 bolnikov, ki so prejemali placebo, stabilnih ravni hemoglobina, povprečno pa so potrebovali deset transfuzij.
In comparison, none of the five enzymes increased with increasing doses of imepitoin.
Za primerjavo se ni noben od teh petih encimov zvišal z večanjem odmerkov imepitoina.
In COMPAS it was 66.7% (95% CI: 21.8-85.9; 7 versus 21 cases).
je bila 15.1 % (95 % IZ: -15,5; 37,6) in 26,3 % (95 % IZ: 4,4; 43,2).
In completed clinical trials, uptake of florbetaben (18F) in 7 predefined cortical areas of the brain (frontal, parietal, lateral and medial temporal, occipital, caudate, posterior cingulate/precuneus cortex, and anterior cingulate gyrus) and cerebellar cortex was measured quantitatively using standardized uptake values (SUV).
Pri zaključenih kliničnih preskušanjih so privzem [18F]florbetabena na 7 vnaprej opredeljenih kortikalnih možganskih območjih (frontalna, parietalna, lateralna in medialna temporalna, okcipitalna, kavdatna, zadnja cingularna skorja/precuneus, sprednja cingularna vijuga) in cerebelarni skorji merili količinsko s standardiziranimi vrednostmi privzema (standardized uptake values – SUV).
In completed clinical trials, uptake of florbetapir (18F) in 6 predefined cortical areas of the brain (precuneus, frontal, anterior cingulate, posterior cingulate, parietal and temporal) was measured quantitatively using standardised uptake values (SUV).
Pri zaključenih kliničnih preskušanjih so privzem florbetapirja (18F) v šest vnaprej opredeljenih kortikalnih možganskih območij (precuneus, frontalna skorja, sprednja cingularna vijuga, zadnja cingularna vijuga, parietalna skorja, temporalna skorja) merili količinsko s standardiziranimi vrednostmi privzema (standardised uptake values - SUV).
In consequence there is a temperature fluctuation, which in its turn causes a fluctuating pressure in the front chamber of the infrared detector.
To vodi v nihanje temperature, ki povzroči nihanje pritiska v prednji komori infrardečega detektorja.
In consequence, as soon as the pandemic is declared (Phase 6 of the WHO global Influenza preparedness plan) and the pandemic vaccine is used, the MAH shall submit periodic safety update reports with periodicity and format defined as follows:
Posledično bo imetnik dovoljenja za promet z zdravilom, takoj po razglasitvi pandemije (faza 6 globalnega načrta SZO o pripravljenosti na gripo) in uporabi pandemskega cepiva, predložil redna posodobljena poročila o varnosti zdravila s pogostnostjo in obliko, ki je definirana, kot sledi:
In consequence, dose adjustment should not be made more frequently than once a month, unless clinically indicated.
Zato se odmerka ne sme prilagajati pogosteje kot enkrat na mesec, razen če je klinično indicirano.
In contrast to phosphocysteamine, another active substance close to cysteamine bitartrate, CYSTAGON does not contain phosphate.
V nasprotju s fosfocisteaminom, ki je druga zdravilna učinkovina, sorodna cisteaminijevemu bitartratu, CYSTAGON ne vsebuje fosfata.
In contrast to the two confirmative studies, a history of chronic bronchitis and of COPD exacerbations was not requested for patients’ inclusion.
Za razliko od dveh potrditvenih študij anamneza kroničnega bronhitisa in poslabšanj KOPB ni bila pogoj za vključitev bolnikov v študijo.
In contrast to these data with
bolnikih na stabilnem odmerku teh
In contrast to these data with
V nasprotju s podatki za kombinacijo
In contrast with systemically administered cytarabine which is rapidly metabolised to ara-U, conversion to ara-U in the CSF is negligible after intrathecal administration because of the significantly lower cytidine deaminase activity in the CNS tissues and CSF.
V primerjavi s sistemsko danim citarabinom, ki se hitro presnovi v ara-U, je pretvorba v ara-U v cerebrospinalni tekočini po intratekalnem odmerjanju zanemarljiva zaradi značilno manjše aktivnosti citidin deaminaze v tkivih osrednjega živčevja in cerebrospinalni tekočini.
In contrast, 10 of 48 doxorubicin subjects who had cardiac toxicity by LVEF criteria also developed signs and symptoms of CHF.
Nasprotno pa je 10 od 48 bolnikov na standardnem doksorubicinu s kardiotoksičnostjo po merilih iztisnega deleža, dobilo tudi znake in simptome kongestivnega srčnega popuščanja.
In contrast, exposure to other people’s cigarette smoke may decrease the amount of insulin your body absorbs.
V nasprotju s tem lahko izpostavljenost dimu cigaret, ki jih kadijo drugi, zmanjša količino insulina, ki se vam absorbira v vašem telesu.
In contrast, exposure to sirolimus was commensurately reduced in paediatric patients, such that the net exposure as measured by the sum of temsirolimus and sirolimus AUCs (AUCsum) was comparable to that for adults.
Nasprotno pa je bila izpostavljenost sirolimusu pri pediatričnih bolnikih sorazmerno manjša, tako da je bila neto izpostavljenost, merjena z vsoto vrednosti AUC temsirolimusa in sirolimusa (AUCsum), primerljiva z izpostavljenostjo, ugotovljeno pri odraslih.
In contrast, if concomitant ciclosporin treatment is stopped, an increase in MPA AUC of around 30% should be expected.
Če pa sočasno zdravljenje s ciklosporinom prekinemo, lahko pričakujemo povečanje AUC mikofenolne kisline za približno 30 %.
In contrast, in low-grade tumours (WHO-grade I and II, e.g. medulloblastoma, oligodendroglioma) no fluorescence could be observed after application of the active substance.
V nasprotju s tem, pri tumorjih nizke stopnje (I. in II. stopnje po SZO, npr. meduloblastomih, oligodendrogliomih) po uporabi zdravilne učinkovine ni mogoče opaziti fluorescence.
In contrast, intrathecal administration of 30 mg free cytarabine has shown a biphasic CSF concentration profile with a terminal phase half-life of about 3.4 hours.
V nasprotju s tem je intratekalno odmerjanje 30 mg prostega citarabina pokazalo dvofazni profil koncentracije v cerebrospinalni tekočini z razpolovnim časom terminalne faze približno 3,4 ure.
In contrast, naltrexone tested positive in the following assays: Drosophila recessive lethal frequency assay, non-specific DNA damage in repair tests with E. coli and WI-38 cells, and urinalysis for methylated histidine residues.
Pozitivne rezultate pa je imel naltrekson pri naslednjih preskusih: preskus recesivne letalne frekvence pri vinskih mušicah, nespecifične poškodbe DNA pri testih popravljanja z E. coli in celicami WI-38 ter analiza urina za metilirane ostanke histidina.
In contrast, the administration of eltrombopag 2 hours before or 4 hours after a high-calcium meal or with low-calcium food [< 50 mg calcium] did not alter plasma eltrombopag exposure to a clinically significant extent (see sections 4.2 and 5.2).
Nasprotno pa odmerjanje eltrombopaga 2 uri pred ali 4 ure po obroku z veliko vsebnostjo kalcija ali skupaj z obrokom z majhno vsebnostjo kalcija [< 50 mg kalcija] ni vplivalo na koncentracijo eltrombopaga v plazmi v klinično pomembnem obsegu (glejte poglavji 4.2 in 5.2).
In contrast, the Class II collagenases (δ, ε, and ζ,) are products of colH gene, their initial cleavage sites are located within the interior of the collagen molecule, and generate smaller collagen fragments.
Nasprotno pa so kolagenaze razreda II (δ, ε, in ζ,) produkti gena colH, njihova cepilna mesta se nahajajo znotraj kolagenske molekule in proizvajajo manjše kolagenske fragmente.
In contrast, the rate of ALT elevations in subjects using other types of estrogens as typically used in hormonal replacement therapy (i.e., oral and topical estradiol and conjugated estrogens) was similar to the rate observed in subjects who were not using estrogen- containing products (approximately 1% in each group).
V nasprotju s tem so bila zvišanja ALT pri tistih, ki so uporabljale druge vrste estrogenov, kakršni se običajno uporabljajo pri hormonskem nadomestnem zdravljenju (tj. peroralni in lokalni estradiol in konjugirani estrogeni), podobna deležu, opaženem med neuporabnicami zdravil z estrogenom (približno 1 % v vsaki skupini).
In contrast, the serum concentration of aztreonam following administration of aztreonam for injection (500 mg) is approximately 54 µg/ml.
Za primerjavo je koncentracija aztreonama v serumu po uporabi aztreonama za injiciranje (500 mg) približno 54 µg/ml.
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of CellCept (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus.
Nasprotno, po dajanju večkratnih odmerkov zdravila CellCept (1,5 g dvakrat na dan) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC takrolimusa povečala za približno 20 % .
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g taken twice a day [BID], morning and evening) were administered to hepatic transplant patients taking tacrolimus.
Nasprotno, po dajanju večkratnih odmerkov mofetilmikofenolata (1,5 g dvakrat na dan, zjutraj in zvečer) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC takrolimusa povečala za približno 20 %.
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5°g taken twice a day [BID], morning and evening]) were administered to hepatic transplant patients taking tacrolimus.
Nasprotno, po dajanju večkratnih odmerkov mofetilmikofenolata (1,5 g dvakrat na dan, zjutraj in zvečer) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC takrolimusa povečala za približno 20 %.
In contrast, there was no effect of Vectibix in the patients with mutated KRAS in their tumours, with both groups of patients living for an average of around 8.0 weeks without their disease getting worse.
V nasprotju s tem pa niso ugotovili nobenega učinka zdravila Vectibix pri bolnikih z mutiranim genom KRAS v tumorjih, saj je čas do napredovanja bolezni pri obeh skupinah bolnikov v povprečju znašal okoli 8,0 tedna.
In contrast, there were 165 (29.8%) events in the IFN+Ara-C arm, of which 130 occurred during first-line treatment with IFN+Ara-C.
C 165 (29,8 %) dogodkov, od tega se jih je 130 zgodilo v času zdravljenja z IFN+Ara-C kot zdravilom prvega izbora.
In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, ,blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis).
V kontroliranih in odprtih študijah pri odraslih in otrocih z zdravilom Humira so poročali o resnih okužbah (vključno s smrtno nevarnimi, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana ali zunajpljučna histoplazmoza, blastomikoza, kokidioidomikoza, pnevmocistoza, kandidaza, aspergiloza in listerioza).
In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis candidiasis, aspergillosis and listeriosis).
V kontroliranih in odprtih študijah pri odraslih in otrocih z zdravilom Humira so poročali o resnih okužbah (vključno s smrtno nevarnimi okužbami, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana ali zunajpljučna histoplazmoza, blastomikoza, kokcidioidomikoza, pnevmocistoza, kandidaza, aspergiloza in listerioza).
In controlled and open label adult and paediatric studies with Humira, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated or extrapulmonary histoplasmosis, blastomycosis, coccidioidomycosis, pneumocystis, candidiasis, aspergillosis and listeriosis).
V kontroliranih in odprtih študijah pri odraslih in otrocih z zdravilom Humira so poročali o resnih okužbah (vključno s smrtno nevarnimi okužbami, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana ali zunajpljučna histoplazmoza, blastomikoza, kokcidioidomikoza, pnevmocistoza, kandidaza, aspergiloza in listerioza).
In controlled and open label studies with Trudexa, serious infections (including fatal infections, which occurred rarely) have been reported, which include reports of tuberculosis (including miliary and extra-pulmonary locations) and invasive opportunistic infections (e.g. disseminated histoplasmosis, pneumocystis carinii pneumonia, aspergillosis and listeriosis).
V kontroliranih in odprtih študijah s Trudexo so poročali o resnih okužbah (vključno s smrtno nevarnimi, ki so se pojavile redko), med katerimi so bile tuberkuloza (tudi miliarna in zunajpljučna) in invazivne oportunistične okužbe (npr. diseminirana histoplazmoza, pljučnica zaradi Pnevmocystis Carinii, aspergiloza in listerioza).
In controlled and uncontrolled periods of the UC pivotal trials with a mean follow-up of 1 year, the incidence of mild ALT elevations was 19.4% in patients receiving golimumab during the maintenance portion of the UC study.
V kontroliranih in nekontroliranih obdobjih ključnih preskušanj pri bolnikih z UK z medianim trajanjem spremljanja bolnikov približno 2 leti je bil delež bolnikov z blagimi zvišanji ALT med vzdrževalnim delom študije UK med prejemniki golimumaba 24,7 %.
In controlled and uncontrolled portions of the studies with a median follow-up of approximately 2 years, the incidence per 100 subject-years of upper respiratory tract infections was 36.0 events; 95% CI: 34.9, 37.2 for golimumab treated patients.
V kontroliranih in nekontroliranih delih študij z medianim trajanjem spremljanja bolnikov približno 4 leta je bila incidenca okužb zgornjih dihal na 100 preiskovanec-let 34,9 dogodka; 95 % IZ: 33,8, 36,0 za bolnike, zdravljene z golimumabom.
In controlled and uncontrolled portions of the trials with a median follow-up of approximately 2 years, the incidence per 100 subject-years of infections was 83.5 events; 95% CI: 81.8, 85.3 for golimumab treated patients.
V kontroliranih in nekontroliranih delih preskušanj z medianim trajanjem spremljanja bolnikov približno 4 leta je bila incidenca okužb na 100 preiskovanec-let 81,1 dogodka; 95 % IZ: 79,5, 82,8 za bolnike, zdravljene z golimumabom.
In controlled clinical studies in patients with AIDS-KS against a bleomycin/vincristine regimen, opportunistic infections were apparently more frequent during treatment with Caelyx.
V nadzorovanih kliničnih raziskavah pri z aidsom povezanem Kaposijevem sarkomu so bile oportunistične okužbe med zdravljenjem z zdravilom Caelyx očitno pogostejše kot med zdravljenjem s kombinacijo bleomicina in vinkristina.
In controlled clinical studies, 10 patients (0.5%) experienced a seizure out of 2051 patients treated with a daily dose of 160 mg enzalutamide, whereas one patient (< 0.1%) receiving placebo and one patient (0.3%) receiving bicalutamide, experienced a seizure.
V nadzorovanih kliničnih študijah je 10 (0,5 %) od 2.051 bolnikov, zdravljenih z dnevnim odmerkom enzalutamida 160 mg, doživelo konvulzije, medtem ko je konvulzije doživel en bolnik (< 0,1 %), ki je dobival placebo, in en bolnik (0,3 %), ki je prejemal bikalutamid.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/or AST  3 X ULN, consecutive) was 1.0 % for patients treated with Pelzont with or without a statin.
V kontroliranih kliničnih študijah je bila pri bolnikih, ki so prejemali zdravilo Pelzont (s statinom ali brez njega), incidenca klinično pomembnih zvišanj serumskih transaminaz (ALT in/ali AST  3 x ZMN, zaporedno) 1,0 %.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/or AST  3 X ULN, consecutive) was 1.0 % for patients treated with Tredaptive with or without a statin.
V kontroliranih kliničnih študijah je bila pri bolnikih, ki so prejemali zdravilo Tredaptive (s statinom ali brez njega), incidenca klinično pomembnih zvišanj serumskih transaminaz (ALT in/ali AST  3 x ZMN, zaporedno) 1,0 %.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/or AST  3 X ULN, consecutive) was 1.0 % for patients treated with Trevaclyn with or without a statin.
V kontroliranih kliničnih študijah je bila pri bolnikih, ki so prejemali zdravilo Trevaclyn (s statinom ali brez njega), incidenca klinično pomembnih zvišanj serumskih transaminaz (ALT in/ali AST  3 x ZMN, zaporedno) 1,0 %.
In controlled clinical studies, use of Epoetin alfa and other erythropoiesis-stimulating agents (ESAs) have shown:
V kontroliranih kliničnih študijah je prišlo pri uporabi epoetina alfa in drugih ESA do:
In controlled clinical studies, use of Epoetin alfa and other ESAs have shown:
V kontroliranih kliničnih študijah je prišlo pri uporabi epoetina alfa in drugih ESA do:
In controlled clinical studies, use of epoetin alfa and other ESAs have shown:
V nadzorovanih kliničnih študijah je uporaba epoetina alfa in drugih ESA pokazala:
In controlled clinical studies, use of epoetins alfa and other ESAs have been associated with decreased locoregional tumour control or decreased overall survival:
V nadzorovanih kliničnih študijah je bila uporaba epoetinov alfa in drugih ESA povezana z zmanjšanim lokoregionalnim nadzorom tumorjev ali zmanjšanim skupnim preživetjem:
In controlled clinical studies, use of epoetins has shown:
V nadzorovanih kliničnih študijah je uporaba epoetinov pokazala: